Get the Stockscreener App
5.405
5.01%
-0.285
Transcode Therapeutics Inc stock is traded at $5.405, with a volume of 3,403.
It is down -5.01% in the last 24 hours and down -19.69% over the past month.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
See More
Previous Close:
$5.69
Open:
$5.3
24h Volume:
3,403
Relative Volume:
0.07
Market Cap:
$5.13M
Revenue:
-
Net Income/Loss:
$-40.36M
P/E Ratio:
-0.1111
EPS:
-48.648
Net Cash Flow:
$-21.40M
1W Performance:
-3.48%
1M Performance:
-19.69%
6M Performance:
-43.17%
1Y Performance:
-24.98%
1-Day Range:
$5.30
$5.43
1-Week Range:
$4.50
$5.82
52-Week Range:
$3.82
$20.99
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
5.3951 | 5.41M | 0 | -40.36M | -21.40M | -48.65 |
VRTX
Vertex Pharmaceuticals Inc
|
445.25 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
615.05 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
905.78 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
285.50 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.16 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid No RevenueAnalyst Earnings Estimate - newsline.com
Daily Brief Health Care: Parabilis Medicines, Integral Diagnostics, Healthequity Inc, ICON PLC, KT Medical Service, Leong Guan Holdings, Oramed Pharmaceuticals , Otsuka Holdings, Crism Therapeutics, TransCode Therapeutics and more - Smartkarma
Inside a new colorectal cancer trial: TransCode’s June 18 webcast with Harvard oncologist - Stock Titan
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid Continued Pipeline DevelopmentMid-Term Outlook - newsline.com
Exclusive: TransCode's RNA therapeutic achieves 64% stable disease rate in colorectal cancer phase 1 study - MSN
TransCode Therapeutics (RNAZ) Advances to Phase 2a Following Pos - GuruFocus
RNAZ | TransCode Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
TransCode Therapeutics Advances TTX-MC138 After Positive Phase 1a - TipRanks
TransCode completes phase 1a trial of cancer drug TTX-MC138 By Investing.com - Investing.com Australia
TransCode Therapeutics (RNAZ) sees clean Phase 1a safety, 64% stable disease with TTX-MC138 - Stock Titan
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer - PR Newswire
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study - Benzinga
Cancer trial drug keeps tumors stable in 64% patients, without dose limits - Stock Titan
TransCode Therapeutics (RNAZ) proxy bundles big equity, financing and director votes - Stock Titan
TransCode Therapeutics sets date for 2026 annual meeting and proposal deadlines - Investing.com Nigeria
TransCode Sets Key Deadlines for 2026 Shareholder Meeting - TipRanks
TransCode Therapeutics, Inc. Files Form 8-K with NASDAQ Listing and Company Details (RNAZ) - Minichart
TransCode Therapeutics sets date for 2026 annual meeting and proposal deadlines By Investing.com - Investing.com South Africa
TransCode Therapeutics (RNAZ) sets July 2, 2026 annual meeting and June 11 proposal cutoff - Stock Titan
(RNAZ) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease - citybuzz -
TransCode initiates phase 2a trial for colorectal cancer drug By Investing.com - Investing.com Australia
TransCode Therapeutics Initiates Phase 2a Clinical Trial With TTX-MC138 in Patients With CtDNA Positive Colorectal Cancer - Moomoo
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer - PR Newswire
TransCode Therapeutics (RNAZ) Drops 10.66%: Support at $5.3 Faces Critical Test After Sharp DeclineCTA Positioning - The Legal Advocate
TransCode Therapeutics Files 8-K/A Detailing Nasdaq Compliance Plan and Soliciting Material Disclosure - Minichart
Nasdaq warns TransCode (NASDAQ: RNAZ) on equity shortfall and delisting risk - Stock Titan
TransCode Therapeutics (RNAZ) Gains Over 2% as Biotech Stock Tests Key Resistance LevelsStop Hunt - newsline.com
TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice - TipRanks
TransCode Therapeutics (RNAZ) Surges 2% as Biotech Stock Tests Key Resistance at $6.55Head and Shoulders - Newser
TransCode Therapeutics (NASDAQ: RNAZ) warned on Nasdaq equity shortfall - Stock Titan
[EFFECT] Transcode Therapeutics, Inc. SEC Filing - Stock Titan
What TransCode Therapeutics RNAZ flagged as biggest challenges ahead Q4 2024 Below ExpectationsQuarterly Earnings - Newser
TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Transcode Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Mesa Air Group, Inc.Common Stock (NQ: MESA - FinancialContent
What you need to know before buying TransCode Therapeutics (RNAZ) (Breakdown Watch) 2026-05-11Fast Rising Picks - newser.com
What TransCode Therapeutics (RNAZ) flagged as biggest challenges ahead | Q4 2024: Below ExpectationsHigh Interest Stocks - newser.com
Trading Systems Reacting to (RNAZ) Volatility - Stock Traders Daily
TransCode Therapeutics (RNAZ) asks shareholders to OK preferred conversions, SEPA funding - Stock Titan
How TransCode Therapeutics (RNAZ) differentiates itself from competitors (Near Highs) 2026-05-08Open Stock Signal Network - newser.com
TransCode Therapeutics 2025 10-K/A: Executive Compensation, Board Members, and Corporate Governance Overview - Minichart
TransCode Registers 1.53 Million Shares for YA II PN Resale Under Equity Purchase Deal - marketscreener.com
TransCode Therapeutics (NASDAQ: RNAZ) registers 15.96M resale shares by selling holders - Stock Titan
TransCode Therapeutics (NASDAQ: RNAZ) updates 2025 governance, executive pay and ownership - Stock Titan
MSN Money - MSN
TransCode names Anna Moore scientific board chair - Investing.com UK
TransCode Therapeutics Appoints Dr. Anna Moore as Scientific Advisory Board Chair, Signs Research Agreement with Michigan State University - citybuzz -
TransCode names Anna Moore scientific board chair By Investing.com - Investing.com Australia
Transcode Therapeutics appoints Dr. Anna Moore as chair of scientific advisory board - marketscreener.com
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
1.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):